«上一篇/Previous Article|本期目录/Table of Contents|下一篇/Next Article»

《中华肺部疾病杂志》[ISSN:1006-6977/CN:61-1281/TN]

卷:

期数:

2020年04期

页码:

470-474

栏目:

论著

出版日期:

2020-08-20

文章信息/Info

Title:

Clinical efficacies of Afatinib and cisplatin combined with pemetrexed in treatment of advanced non-small cell lung cancer

作者:

郑云威¹ 黄国定² 卢宏全²

571799 儋州,海南省儋州市中医医院肺病科¹ 571700 海口,海南西部医院肿瘤内科²

Author(s):

Zheng Yunwei¹;  Huang Guoding²;  Lu Hongquan².

¹Department of Pulmonology, Danzhou Traditional Chinese Medicine Hospital, Danzhou 571799, Hainan Province, China; ²Department of Oncology, Hainan West Hospital, Haikou 571700, Hainan Province, China
Corresponding author

关键词:

非小细胞肺癌;  阿法替尼;  顺铂;  培美曲塞;  疗效

Keywords:

Non-small cell lung cancer;  Afatinib;  Cisplatin;  Pemetrexed;  Curative effect

分类号:

R563,R734.2

DOI:

10.3877/cma.j.issn.1674-6902.2020.04.008

摘要:

目的 探究阿法替尼和顺铂分别联合培美曲塞治疗晚期EFGR突变型非小细胞肺癌晚期(non-small-cell carcinoma, NSCLC)的临床疗效差异,明确阿法替尼临床疗效。方法 选取我院2016年3月至2017年9月收治的107例EFGR突变阳性晚期NSCLC患者的病例资料,接受顺铂+培美曲治疗的NSCLC患者51例为对照组,接受塞阿法替尼+培美曲塞治疗的NSCLC患者56例,为研究组,观察两组患者疗效、无进展生存时间(progression-free survival time, PFS)以及生存时间(overall survival, OS)等。结果 研究组患者ORR及DCR比例均明显高于对照组[53.57% vs. 31.37%,85.71% vs. 66.67%,P<0.05]; 研究组患者PFS及OS均明显高于对照组[7.2月 vs. 6.0月,11.75月 vs. 9.5月,P<0.05]; 治疗后,研究组患者神经元特异性烯醇化酶(neuron-specific enolase, NSE)、癌胚抗原(carcinoembryonic antigen, CEA)、细胞角蛋白19片段(cytokeratin 19 fragment, CYFRA21-1)均低于对照组[(11.79±8.51)ng/ml vs.(15.26±8.22)ng/ml,(14.54±8.77)ng/ml vs.(18.37±9.35)ng/ml,(3.45±2.68)ng/ml vs.(5.41±3.54)ng/ml,P<0.05]; Ⅰ～Ⅱ级不良反应中,研究组恶心呕吐、肾功能损害及脱发人数比例均明显低于对照组[12.50% vs. 33.33%,5.36% vs. 27.45%,16.07% vs. 35.29%,P<0.05],研究组皮疹/痤疮人数比例明显高于对照组[25.00% vs. 7.84%,P<0.05]; 治疗后,躯体方面、心理方面、社会方面及总体感觉评分均高于对照组[(77.41±5.25)分 vs.(72.12±5.08)分,(74.37±5.40)分 vs.(67.52±5.32)分,(79.25±5.98)分 vs.(74.32±5.71)分,(71.21±5.45)分 vs.(66.61±5.20)分,P<0.05]。结论 阿法替尼联合培美曲塞一线治疗EGFR突变型晚期NSCLC患者的疗效更为显著,明显提高无进展生存时间及生存时间,明显提高生活质量,同时具有较高安全性,值得临床推广应用。

Abstract:

Objective To investigate the difference of clinical efficacies of Afatinib and cisplatin combined with pemetrexed respectively in the treatment of the patients with advanced EFGR mutant non-small cell lung cancer(NSCLC)so as to determine the clinical efficacy of Afatinib. Methods A total of 107 patients with advanced EFGR mutant NSCLC treated in our hospital from March 2016 to September 2017 were selected for this study. Fifty-one patients treated with cisplatin+pemetrexed were taken as the control group, while fifty-six patients treated with Afatinib+pemetrexed were taken as the experimental group. The clinical efficacies, the progression-free survival time(PFST), and the overall survival(OS)were observed for all the patients. Results The proportions of ORR and DCR in the experimental group were significantly higher than those of the control group(53.57% vs. 31.37% and 85.71% vs. 66.67%, respectively, P<0.05). The PFST and OS were significantly higher in the experimental group than the control group(7.2 months vs. 6.0 months and 11.75 months vs. 9.5 months, respectively, P<0.05). After treatment, the neuron-specific enolase(NSE), carcinoembryonic antigen(CEA), and cytokeratin 19 fragment(CYFRA21-1)of the experimental group were lower than those of the control group [(11.79±8.51)ng/ml vs.(15.26±8.22)ng/ml,(14.54±8.77)ng/ml vs.(18.37±9.35)ng/ml, and(3.45±2.68)ng/ml vs.(5.41±3.54)ng/ml, respectively, P<0.05]. The incidences of nausea and vomiting, renal impairment and hair loss in the experimental group were significantly lower than those of the control group(12.50% vs. 33.33%, 5.36% vs. 27.45%, and 16.07% vs. 35.29%, respectively, P<0.05). The incidence of rash/acne in the experimental group was significantly higher than that of the control group(25.00% vs. 7.84%, P<0.05). After treatment, the physical, psychological, social and overall sensory scores were higher in the experimental group than the control group [(77.41±5.25)scores vs.(72.12±5.08)scores,(74.37±5.40)scores vs.(67.52±5.32)scores,(79.25±5.98)scores vs.(74.32±5.71)scores, and(71.21±5.45)scores vs.(66.61±5.20)scores, respectively, P<0.05]. Conclusion Afatinib combined with pemetrexed is more effective in the first-line treatment of advanced EGFR mutant NSCLC patients, significantly improves the PFST, the OS and the quality of life of the patients, and has a higher safety, which is worthy of clinical promotion and application.

参考文献/References:

1 Hirsch FR, Scagliotti GV, Mulshine JL, et al. Lung cancer: current therapies and new targeted treatments[J]. Lancet, 2017, 389(10066): 299-311.
2 Zappa C, Mousa SA. Non-small cell lung cancer: current treatment and future advances[J]. Translat Lung Cancer Res, 2016, 5(3): 288.
3 Herbst RS, Morgensztern D, Boshoff C. The biology and management of non-small cell lung cancer[J]. Nature, 2018, 553(7689): 446-454.
4 刘 洋, 周 莹, 阳 韬, 等. 血清结合珠蛋白在非小细胞肺癌诊治中的意义[J]. 江苏大学学报(医学版), 2017, 27(6): 530-532.
5 Fennell DA, Summers Y, Cadranel J, et al. Cisplatin in the modern era: The backbone of first-line chemotherapy for non-small cell lung cancer[J]. Cancer Treatment Reviews, 2016, 44: 42-50.
6 王玉娟, 王 莉, 康 睿. 培美曲塞与吉西他滨分别联合顺铂治疗晚期非鳞非小细胞肺癌效果及对基质金属蛋白酶及其抑制剂水平影响研究[J]. 临床和实验医学杂志, 2017, 16(12): 1193-1195.
7 Qin X, Yu S, Zhou L, et al. Cisplatin-resistant lung cancer cell-derived exosomes increase cisplatin resistance of recipient cells in exosomal miR-100-5p-dependent manner[J]. Int J Nanomed, 2017, 12: 3721.
8 Chen N, Fang W, Zhan J, et al. Upregulation of PD-L1 by EGFR activation mediates the immune escape in EGFR-driven NSCLC: implication for optional immune targeted therapy for NSCLC patients with EGFR mutation[J]. J Thorac Oncol, 2015, 10(6): 910-923.
9 Yue D, Xu S, Wang Q, et al. Erlotinib versus vinorelbine plus cisplatin as adjuvant therapy in Chinese patients with stage ⅢA EGFR mutation-positive non-small-cell lung cancer(EVAN): a randomised, open-label, phase 2 trial[J]. Lancet Respirat Med, 2018, 6(11): 863-873.
10 Sharma N, Graziano S. Overview of the LUX-Lung clinical trial program of afatinib for non-small cell lung cancer[J]. Cancer Treat Rev, 2018, 69: 143-151.
11 Park K, Yu CJ, Kim SW, et al. First-line erlotinib therapy until and beyond response evaluation criteria in solid tumors progression in Asian patients with epidermal growth factor receptor mutation-positive non-small-cell lung cancer: the ASPIRATION study[J]. JAMA Oncol, 2016, 2(3): 305-312.
12 罗 健, 孙 燕, 周生余. 中国癌症患者化学生物治疗生活质量量表的编制[J]. 中华肿瘤杂志, 1997,17(6): 437-441.
13 罗华婷, 刘 锐, 陈 川, 等. 阿法替尼治疗EGFR突变型晚期非小细胞肺癌的有效性及安全性的研究[J]. 肿瘤药学, 2015, 12(6): 466-471.
14 李 倩, 李 宵, 李 颖, 等. 阿法替尼治疗晚期非小细胞肺癌有效性和安全性的系统评价[J]. 中国循证医学杂志, 2017, 9(8): 66-71.
15 潘 燚, 谭佩欣. 一线阿法替尼与化疗对EGFR突变伴有脑转移的非小细胞肺癌患者的疗效评价[J]. 循证医学, 2016, 16(4): 230-232.
16 杨小菊, 欧 娜, 赵 盼, 等. 阿法替尼治疗肺癌的临床研究进展[J]. 药学进展, 2017, 41(4): 297-304.
17 龚 磊. 阿法替尼在非小细胞肺癌中的临床应用进展[J]. 中国肿瘤, 2018, 27(11): 857-861.
18 施 霞. 阿法替尼和吉非替尼一线治疗EGFR突变阳性非小细胞肺癌的成本效用分析[J]. 中国现代应用药学, 2019, 36(21): 2701-2706.
19 薛英杰, 贾 靖, 吴 杨, 等. 培美曲塞和吉西他滨联合阿法替尼治疗晚期非小细胞肺癌临床效果及安全性分析[J]. 临床误诊误治, 2020, 33(2): 57-60.
20 刘 涛, 闫平钊, 杨小花, 等. 阿法替尼在老年非小细胞肺癌患者中的应用[J]. 中国老年学杂志, 2019, 39(16): 3931-3933.
21 肖 敬, 程晓云, 张淑平, 等. 固摄扶正抗癌汤联合阿法替尼、培美曲塞治疗非小细胞肺癌的临床效果观察[J]. 解放军医药杂志, 2019, 31(11): 20-23.
22 王萌萌, 苏颖杰, 严颐丹. 临床药师对1例贝伐珠单抗联合阿法替尼治疗宫颈癌复发转移患者的药学监护[J]. 中国临床药学杂志, 2019, 28(6): 465-467.
23 贵永贤. 重组人血管内皮生成抑制素联合阿法替尼治疗EGFR突变阳性晚期肺腺癌患者的临床效果[J]. 临床医学研究与实践, 2020, 5(5): 29-30.
24 谭鑫宇, 张 欢, 张 杰, 等. 阿法替尼治疗非小细胞肺癌患者致严重的药品不良反应影响因素的Logistic回归分析[J]. 中国医院用药评价与分析, 2019, 19(9): 1131-1133.
25 马晓东, 胡孟奇, 陶强强. 马来酸阿法替尼原料药降解杂质的制备与结构推测[J]. 化学世界, 2019, 60(3): 177-181.
26 赵仔君, 谷晓媛, 张为强, 等. 贝伐珠单抗联合阿法替尼治疗非小细胞肺癌临床疗效观察[J]. 海南医学院学报, 2019, 25(2): 129-132.
27 龚 磊, 卢红阳. 阿法替尼在非小细胞肺癌中的临床应用进展[J]. 中国肿瘤, 2018, 27(11): 857-861.
28 薛英杰, 贾 靖, 吴 杨, 等. 阿法替尼分别联合培美曲塞、吉西他滨治疗非小细胞肺癌的临床研究[J]. 空军医学杂志, 2019, 35(1): 28-31.

备注/Memo

备注/Memo:

基金项目: 海南省2015年社会发展科技专项基金(SQ2015SHFZ01741)
通信作者: 郑云威, Email: zhengweiyun@163.com

常用功能

更新日期/Last Update: 2020-08-20